FLGT (Fulgent Genetics, Inc.) Stock Financials & Earnings

FLGTFulgent Genetics, Inc.

Mkt Cap$458M

Revenue (TTM)$323M

Net Income (TTM)-$61M

EPS (TTM)-$1.95

Free Cash Flow (TTM)-$124M

Gross Margin40.6%

Op. Margin-28.2%

Net Margin-18.8%

FCF Margin-38.5%

P/S Ratio (TTM)1.4x

P/E Ratio (TTM)—

YoY Rev Growth+13.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$66M	$19M	-$25M
Q2 23	$68M	$21M	-$20M
Q3 23	$85M	$40M	$214K
Q4 23	$71M	$25M	-$151M
Q1 24	$64M	$22M	-$22M
Q2 24	$71M	$26M	-$19M
Q3 24	$72M	$27M	-$17M
Q4 24	$76M	$32M	-$16M
Q1 25	$73M	$28M	-$20M
Q2 25	$82M	$34M	-$20M
Q3 25	$84M	$36M	-$15M
Q4 25	$83M	$33M	-$36M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$10M	$22M	$10M
Q2 23	$10M	$18M	$11M
Q3 23	$10M	$17M	$10M
Q4 23	$12M	$32M	$11M
Q1 24	$11M	$21M	$9M
Q2 24	$13M	$21M	$9M
Q3 24	$12M	$21M	$9M
Q4 24	$12M	$24M	$10M
Q1 25	$12M	$25M	$8M
Q2 25	$13M	$26M	$12M
Q3 25	$14M	$23M	$12M
Q4 25	$14M	$42M	$11M

Revenue Segments

Revenue by Geography

Quarter	Non-US	United States	China	Other Countries
Q1 23	$4M	$62M	—	—
Q2 23	$5M	$63M	—	—
Q3 23	$6M	$79M	—	—
Q4 23	$6M	$65M	—	—
Q1 24	—	$58M	$4M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$66M	$438M	$504M
Q2 23	$58M	$400M	$458M
Q3 23	$84M	$384M	$468M
Q4 23	$97M	$327M	$424M
Q1 24	$55M	$251M	$306M
Q2 24	$65M	$247M	$312M
Q3 24	$58M	$155M	$213M
Q4 24	$55M	$203M	$258M
Q1 25	$67M	$253M	$320M
Q2 25	$88M	$205M	$293M
Q3 25	$118M	$258M	$376M
Q4 25	$50M	$286M	$336M

Shares Outstanding

Revenue Per Employee

Revenue / Employee